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Background
Critical illness is often accompanied by hypercortisolemia, which has been attrib-
uted to stress-induced activation of the hypothalamic–pituitary–adrenal axis. How-
ever, low corticotropin levels have also been reported in critically ill patients, which 
may be due to reduced cortisol metabolism.
Methods
In a total of 158 patients in the intensive care unit and 64 matched controls, we 
tested five aspects of cortisol metabolism: daily levels of corticotropin and cortisol; 
plasma cortisol clearance, metabolism, and production during infusion of deuterium-
labeled steroid hormones as tracers; plasma clearance of 100 mg of hydrocortisone; 
levels of urinary cortisol metabolites; and levels of messenger RNA and protein in 
liver and adipose tissue, to assess major cortisol-metabolizing enzymes.
Results
Total and free circulating cortisol levels were consistently higher in the patients than 
in controls, whereas corticotropin levels were lower (P<0.001 for both compari-
sons). Cortisol production was 83% higher in the patients (P = 0.02). There was a 
reduction of more than 50% in cortisol clearance during tracer infusion and after 
the administration of 100 mg of hydrocortisone in the patients (P≤0.03 for both 
comparisons). All these factors accounted for an increase by a factor of 3.5 in plasma 
cortisol levels in the patients, as compared with controls (P<0.001). Impaired cortisol 
clearance also correlated with a lower cortisol response to corticotropin stimulation. 
Reduced cortisol metabolism was associated with reduced inactivation of cortisol 
in the liver and kidney, as suggested by urinary steroid ratios, tracer kinetics, and 
assessment of liver-biopsy samples (P≤0.004 for all comparisons).
Conclusions
During critical illness, reduced cortisol breakdown, related to suppressed expression 
and activity of cortisol-metabolizing enzymes, contributed to hypercortisolemia and 
hence corticotropin suppression. The diagnostic and therapeutic implications for 
critically ill patients are unknown. (Funded by the Belgian Fund for Scientific Re-
search and others; ClinicalTrials.gov numbers, NCT00512122 and NCT00115479; 
and Current Controlled Trials numbers, ISRCTN49433936, ISRCTN49306926, and 
 ISRCTN08083905.)
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Critical illness, an example of se-vere acute physical stress, is often accom-panied by hypercortisolemia that is pro-
portionate to the severity of illness.1,2 This 
observation has traditionally been attributed to 
stress-induced activation of the hypothalamic–
pituitary–adrenal (HPA) axis and increased corti-
cotropin-driven cortisol production.3 However, 
this stress response may not be sufficient for a 
good prognosis in patients with relative adrenal 
insufficiency.4-7 Moreover, Vermes et al.8 reported 
only transiently elevated levels of corticotropin 
during critical illness, whereas cortisol levels re-
mained high, a paradoxical dissociation between 
cortisol and corticotropin levels that has also 
been observed in other stress conditions.9
In addition to alternative activators of cortisol 
production, such as proinflammatory cytokines,9,10 
another explanation for hypercortisolemia in the 
presence of suppressed corticotropin could be re-
duced cortisol removal. The principal routes of 
cortisol clearance occur in the liver (through A-
ring reductases [5β-reductase and 5α-reductase]) 
and kidney (through 11β-hydroxysteroid dehy-
drogenase type 2 [11β-HSD2], which converts 
cortisol to cortisone). This removal is offset by 
the regeneration of cortisol from cortisone 
through 11β-hydroxysteroid dehydrogenase type 
1 (11β-HSD1) in liver and adipose tissue.11,12 The 
regulation of these enzymes is complex.12,13 In 
addition, in critically ill patients, elevated circu-
lating levels of bile acids could be powerful sup-
pressors of the expression and activity of cortisol-
metabolizing enzymes.14-17 We hypothesized that 
cortisol metabolism is reduced during critical ill-
ness, contributing to sustained hypercortisolemia 
with enhanced negative-feedback inhibition of 
corticotropin.
Me thods
Study Design
To test our hypothesis, we performed five clinical 
studies comparing 158 consecutively screened 
patients in the intensive care unit (ICU) with 64 
demographically matched controls (Table 1, and 
Table S1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM 
.org).18,19 In these studies, we measured daily lev-
els of corticotropin and cortisol; plasma cortisol 
clearance, metabolism, and production during 
infusion of deuterium-labeled steroid hormones 
as tracers; plasma clearance of 100 mg of hydro-
cortisone; urinary cortisol metabolites; and lev-
els of messenger RNA (mRNA) and protein in 
liver and adipose tissue to assess major cortisol-
metabolizing enzymes.
Excluded from the study were patients and 
controls who had predisposing risk factors for 
HPA-axis dysfunction, who were receiving con-
traindicated drugs, or who were undergoing ex-
tracorporeal membrane oxygenation or therapy 
with a circulatory-assist device (for details, see 
Methods Sections S1 and S2 and Table S2 in the 
Supplementary Appendix). All samples were 
stored at −80°C.
All study protocols were approved by the in-
stitutional review board at KU Leuven. The study 
protocol and statistical analysis plan are avail-
able at NEJM.org. No commercial entity provided 
support for this study. All participants or their 
representatives provided written informed consent.
Corticotropin–Cortisol Time Course
Morning blood samples were collected daily from 
47 patients for 7 days after admission and from 
12 controls (Table 1). Samples were collected in 
prechilled EDTA tubes, placed on ice, and centri-
fuged at 4°C. Total levels of cortisol (Immunotech) 
and transcortin (DiaSource) were quantified on 
radioimmunoassay and corticotropin levels on 
double-monoclonal immunoradiometric assays 
(Brahms Diagnostics).20,21
Plasma Cortisol Clearance and Production
A total of 11 patients and 9 controls (Table 1) re-
ceived intravenous deuterated cortisol (D4-cortisol, 
Cambridge Isotopes)22 as a 0.7-mg priming bolus, 
followed by continuous infusion of 0.35 mg per 
hour for 3 hours between 10 a.m. and 1 p.m. to 
achieve steady state in the circulation.11,23,24 After 
100 minutes of D4-cortisol infusion, participants 
also received deuterated cortisone (D2-cortisone, 
Cambridge Isotopes)25 as a 0.08-mg priming bolus, 
followed by continuous infusion of 0.1053 mg 
per hour. Blood samples were obtained 5 minutes 
before D4-cortisol infusion and at intervals of 
60, 120, 140, 160, 165, 170, 175, and 180 minutes 
after infusion. In preinfusion samples, plasma lev-
els of corticotropin were measured (as described 
above), and levels of tumor necrosis factor α 
(TNF-α) and interleukin-6 were measured by means 
of enzyme-linked immunosorbent assay (Invitro-
gen). Plasma cortisol was quantified on liquid 
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chromatography–tandem mass spectrometry. 
Tracer analyses and calculations of cortisol ki-
netics are described in Methods Section S3 in the 
Supplementary Appendix.11,25 Ten patients un-
derwent a short corticotropin-stimulation test 
(injection of 250 μg) within 24 hours after tracer 
infusion.
Plasma Clearance of a Therapeutic  
Cortisol Dose
A total of 20 patients and 8 controls (Table 1) 
received a 100-mg intravenous bolus of hydrocor-
tisone (Solu-Cortef). Blood samples were taken 
every 10 minutes for 1 hour and then every hour 
for 4 hours. Cortisol was quantified on radioim-
munoassay, as described above, and pharmacoki-
netic characteristics were calculated (as described 
in Methods Section S4 in the Supplementary Ap-
pendix).
Activity of Cortisol-Metabolizing Enzymes
We collected 24-hour urine samples from 36 pa-
tients and 15 controls, followed by a morning 
blood sample (Table 1). Patients requiring renal-
replacement therapy were excluded. We used liq-
uid chromatography–tandem mass spectrometry 
to estimate levels of urinary cortisol, cortisone, 
5α-tetrahydrocortisol, 5β-tetrahydrocortisol, and 
tetrahydrocortisone, which were quantified on gas 
chromatography–mass spectrometry.26 Activities 
of A-ring reductases and 11β-HSD enzymes were 
estimated (for details, see Methods Section S5 in 
the Supplementary Appendix).26-30 Total bile acids 
were quantified by means of enzymatic cycling 
(Diazyme Laboratories).
Tissue Expression of Cortisol-Metabolizing 
Enzymes
A morning blood sample was obtained on the last 
ICU day, and liver and adipose tissue samples were 
obtained immediately after death from 44 pa-
tients (see Methods Section S6 in the Supplemen-
tary Appendix). For comparison, tissue-biopsy 
and blood samples were collected from 20 con-
trols undergoing elective abdominal surgery (Ta-
ble 1). Tissue samples were snap-frozen in liquid 
nitrogen.
Total tissue mRNA was purified, complemen-
tary DNA was quantified in real time, and the 
results were analyzed (for details, see Methods 
Section S7 in the Supplementary Appendix). West-
ern blotting was performed and the results were 
analyzed (for details, see Methods Section S8 in 
the Supplementary Appendix). Enzyme activity of 
11β-HSD1 and 5β-reductase was determined in 
vitro in hepatic tissue, and activity of 11β-HSD1 
was determined in adipose tissue.31
Total cortisol was quantified with the use of 
chemiluminescence (Immulite 2000, Diagnostic 
Products), and total bile acids were measured, as 
described above.
Statistical Analysis
All data are presented as means ±SD or medians 
with interquartile ranges. We used Wilcoxon rank-
sum tests for data that did not have a normal 
distribution and unpaired Student’s t-tests for 
normally distributed data. Proportions were com-
pared with the use of chi-square tests. Associa-
tions were analyzed with linear regression after 
transformation to approximate normal distribu-
tion when required. We used analysis of variance 
to calculate the significance of Pearson’s deter-
mination coefficients (r2). A two-sided P value of 
less than 0.05 was considered to indicate statisti-
cal significance. All statistical analyses were per-
formed with the use of JMP software, version 9.0.0 
(SAS Institute).
R esult s
Patients versus Controls
Differences between patients and controls applied 
to survivors and nonsurvivors and were not influ-
enced by illness severity, illness duration at the 
time of blood or tissue sampling, or status with 
respect to the use of opioids or anticoagulant 
agents (Tables S2 through S6 in the Supplemen-
tary Appendix).
Plasma Corticotropin and Cortisol Time 
Course
In the presence of elevated total cortisol levels 
(averaged over 7 days, P = 0.01), patients had low-
er corticotropin levels than did controls (P<0.001) 
(Fig. 1). Levels of cortisol did not correlate with 
corticotropin levels. Mean levels of transcortin 
were lower in the patients than in the controls, 
with values for patients on day 1 of 31.6±10.4 mg 
per liter (P = 0.001) and on day 7 of 47.4±11.6 mg 
per liter (P<0.001), as compared with a single mea-
sure of 67.8±8.7 mg per liter in the controls. As a 
consequence, calculated median free cortisol levels 
were higher in the patients than in the controls, 
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with values for patients on day 1 of 1.0 μg per 
deciliter (interquartile range, 0.4 to 2.7 [28 nmol 
per liter; interquartile range, 11 to 74]) and on 
day 7 of 0.9 μg per deciliter (interquartile range, 
0.6 to 1.6 [25 nmol per liter; interquartile range, 
17 to 44]), as compared with a single measure of 
0.4 μg per deciliter (interquartile range, 0.3 to 0.4 
[11 nmol per liter; interquartile range, 8 to 11]) 
in the controls (P≤0.001 for both comparisons).
Cortisol Kinetics during Infusion of Stable 
Isotope Tracers
Steady-state levels and enrichments of D4-cortisol 
and D2-cortisone were achieved from 60 minutes 
onward. In the patients, as compared with the con-
trols, endogenous cortisol levels were increased 
by a factor of 3.5 (P<0.001), and the rate of ap-
pearance of cortisol (hereafter referred to as cor-
tisol production) was increased by 83% (P = 0.02), 
but preinfusion corticotropin levels were reduced 
by 65% (P = 0.03) (Fig. 2A, 2C, and 2D). There was 
no significant difference in cortisol production 
between patients who were treated with catechol-
amines and those who were not treated with cat-
echolamines (2.7±1.3 mg per hour and 2.9±1.4 mg 
per hour, respectively; P = 0.86).
In the patients, as compared with the controls, 
plasma levels of TNF-α were increased by 49% 
(P = 0.001), and plasma interleukin-6 levels were 
increased by more than a factor of 200 (P<0.001). 
Cytokine levels correlated positively with cortisol 
production, with a coefficient of determination 
of 0.26 for TNF-α (P = 0.02) and 0.30 for interleu-
kin-6 (P = 0.01); there also was a positive correla-
tion after correction for corticotropin levels, with 
a coefficient of determination of 0.28 for TNF-α 
(P = 0.03) and 0.30 for interleukin-6 (P = 0.02). 
Consistent with these correlations was the find-
ing that patients with the systemic inflamma-
tory response syndrome19 had 90% higher corti-
sol production than those who did not have the 
syndrome (3.4±1.1 mg per hour vs. 1.8±1.1 mg 
per hour, P = 0.04); the latter value did not differ 
significantly from that of controls (P = 0.39).
In the patients, as compared with the controls, 
D4-cortisol levels during infusion were 57% 
higher (P = 0.04) and plasma clearance of D4-
cortisol was reduced by 53% (P = 0.03) (Fig. 2B 
and 2E). Reduced cortisol clearance did not cor-
relate with markers of organ perfusion (Table S7 
in the Supplementary Appendix).
We tested whether decreased cortisol clear-
ance was associated with evidence of adrenal 
insufficiency in relation to reduced corticotropin 
stimulation. A lower cortisol response to corti-
cotropin stimulation in the patients correlated 
both with lower cortisol production and with 
lower D4-cortisol clearance (Fig. 2F and 2G). 
Patients with a cortisol response to corticotropin 
of less than 21 μg per deciliter (579 nmol per 
liter), a level that is considered indicative of ab-
solute adrenal insufficiency,32 had substantially 
lower D4-cortisol plasma clearance (0.15±0.02 li-
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Figure 1. Dissociation between Corticotropin and Cortisol 
Levels among Patients in the Intensive Care Unit (ICU).
Shown are mean values for cortisol (Panel A) and corti-
cotropin (Panel B) in 47 patients from day 1 to day 7 in 
the ICU. The shaded area represents the interquartile 
range of values in 12 healthy controls. The overall mean 
cortisol levels over the 7-day period were 16.8±7.8 μg 
per deciliter (464±215 nmol per liter) for patients and 
11.9±2.3 μg per deciliter (328±63 nmol per liter) for con-
trols (P = 0.01). The overall mean corticotropin levels 
over the 7-day period were 16.9±9.5 pg per milliliter 
(4±2 pmol per liter) for patients and 49.6±37.9 pg per 
milliliter (11±8 pmol per liter) for controls (P<0.001). 
To convert values for cortisol to nanomoles per liter, 
multiply by 27.6. To convert values for corticotropin to 
picomoles per liter, multiply by 0.22. The I bars indicate 
standard errors.
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ters per minute) than did patients who had a nor-
mal response to corticotropin (0.28±0.11 liters 
per minute; P = 0.01). Cortisol production in pa-
tients with adrenal insufficiency (1.4±0.5 mg per 
hour) was indistinguishable from that in controls, 
whereas it was elevated (3.0±1.3 mg per hour) in 
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study period, in 11 patients and 9 controls. The I bars indicate standard errors. To convert values for D4-cortisol to nanomoles per liter, 
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patients with a normal response to corticotropin 
(P = 0.03). Circulating levels of cortisol before 
corticotropin stimulation were similar in these 
two groups of patients (9.5±1.5 μg per deciliter 
[262±41 nmol per liter] and 11.5±6.5 μg per deci-
liter [317±179 nmol per liter], respectively; P = 0.51).
Tracer analysis also allowed dissection of the 
contribution of 11β-HSD enzymes to altered cor-
tisol clearance.11,25 The patients had a lower net 
rate of appearance of cortisone than the controls 
(0.07±0.02 mg per hour for every microgram per 
deciliter vs. 0.14±0.07 mg per hour for every mi-
crogram per deciliter, P = 0.01). However, there 
was no significant between-group difference in 
the level of regeneration of cortisol by 11β-HSD1, 
as measured by the rate of appearance of D3-
cortisol (0.42±0.12 mg per hour and 0.49±0.12 mg 
per hour, respectively; P = 0.23). These findings 
are consistent with impaired conversion of cor-
tisol to cortisone by 11β-HSD2.
Plasma Clearance of Cortisol
We tested whether altered cortisol metabolism in 
critically ill patients occurs at supraphysiological 
concentrations after the administration of thera-
peutic hydrocortisone. The calculated plasma 
clearance after the administration of 100 mg of 
hydrocortisone in the patients (0.04±0.02 liters 
per minute) was 60% lower than that in the con-
trols (0.10±0.02 liters per minute, P<0.001), with 
a distribution volume that was 37% higher 
(22±10 liters vs. 16±5 liters, P = 0.03) (Fig. S1 in 
the Supplementary Appendix). Cortisol clear-
ance was even more suppressed in nonsurvivors 
(0.02±0.01 liters per minute) than in survivors 
(0.05±0.03 liters per minute, P = 0.03).
Activity of Cortisol-Metabolizing Enzymes
We addressed the contribution of 11β-HSD en-
zymes and A-ring reductases to impaired cortisol 
clearance in the patients. There were no correla-
tions between urinary levels of cortisol metabo-
lites and creatinine clearance or daily urine out-
put, which was similar in patients and controls 
(1936±655 ml vs. 1713±734 ml in 24 hours, 
P = 0.29).33,34 Analysis on liquid chromatography–
tandem mass spectrometry suggested substantial 
changes in relative excretion of cortisol metabo-
lites (Table S8 in the Supplementary Appendix). 
These findings were further quantified on gas 
chromatography–mass spectrometry, which 
showed that the daily urinary excretion of corti-
sol was increased by a factor of 3.2 in the patients, 
as compared with the controls, and urinary excre-
tion of cortisone was 73% higher in the patients 
(P<0.001 for both comparisons). In contrast, levels 
of 5α-tetrahydrocortisol and 5β-tetrahydrocor-
tisol were similar in patients and controls, 
whereas the level of tetrahydrocortisone was re-
duced by 69% in the patients (P<0.001) (Table S9 
in the Supplementary Appendix).
Decreased levels of 11β-HSD2 were confirmed 
in the patients, in whom the ratio of urinary cor-
tisone to cortisol, which reflects the renal 
11β-HSD2 level, and the ratio of 5α-tetra hy dro-
cortisol and 5β-tetrahydrocortisol combined to 
tetrahydrocortisone, which reflects the conver-
sion of cortisol to cortisone, was markedly al-
tered in favor of cortisol (Fig. 3A and 3B). In 
addition, the ratios reflecting activities of A-ring 
reductases were markedly reduced in the pa-
tients, as compared with the controls (Fig. 3C, 
3D, and 3E). Nonsurvivors had lower estimated 
median 5α-reductase activity than survivors (ratio 
of 5α-tetrahydrocortisol to cortisol, 0.6 [interquar-
tile range, 0.2 to 0.8] vs. 1.4 [interquartile range, 
0.8 to 4.2], P = 0.01) but similar 5β-reductase ac-
tivity (ratio of 5β-tetrahydrocortisol to cortisol, 
1.2 [interquartile range, 0.2 to 2.5] and 1.9 [inter-
quartile range, 1.3 to 3.3], respectively; P = 0.14).
Levels of total bile acids were increased by a 
factor of 2.4 in the patients, as compared with the 
controls (10.9±2.5 μmol per liter [4.3±1.0 μg per 
milliliter] vs. 4.6±1.8 μmol per liter [1.8±0.7 μg 
per milliliter]) (P = 0.04) and correlated inversely 
with urinary ratios reflecting A-ring reductase 
activities (Fig. 3F, 3G, and 3H).
Tissue Expression of Cortisol-Metabolizing 
Enzymes
To test the inferences from urinary metabolite 
ratios and tracer kinetics, we studied cortisol-
metabolizing enzymes in tissue-biopsy samples. 
Circulating levels of total cortisol in the patients 
were three times as high as those in the controls 
(24.3 μg per deciliter; interquartile range, 19.6 to 
30.3 [670 nmol per liter; interquartile range, 541 to 
836] vs. 7.4 μg per deciliter; interquartile range, 
4.9 to 14.7 [204 nmol per liter; interquartile range, 
135 to 406], P<0.001). Levels of total bile acids 
were substantially higher in the patients than in 
the controls (P<0.001) (Fig. 4A) and correlated 
positively with cortisol levels (r2 = 0.26, P<0.001).
In liver specimens from the patients, the mRNA 
level and protein expression of 5β-reductase were 
reduced by 80 to 91%, as compared with controls 
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(Fig. 4B and 4C), and enzyme activity was re-
duced by 58% (0.022 pmol per minute per mil-
ligram [interquartile range, 0.012 to 0.029]) vs. 
0.053 pmol per minute per milligram [interquar-
tile range, 0.033 to 0.067], P = 0.01). The mRNA 
level correlated positively with protein expression 
of 5β-reductase (r 2 = 0.46, P<0.001), which in turn 
had a negative correlation with circulating corti-
sol levels (Fig. 4D). The level of total bile acids 
correlated inversely with the mRNA level and pro-
tein expression of 5β-reductase (Fig. 4E and 4F).
The liver mRNA level of 5α-reductase was 
reduced by 77% in patients, as compared with 
controls (ratio, 0.23 [interquartile range, 0.12 to 
0.36] vs. 1.01 [interquartile range, 0.66 to 1.65], 
P<0.001). (The mRNA data, which have been 
normalized for glyceraldehyde-3-phosphate- 
dehydrogenase [GAPDH] expression, are expressed 
as the factor difference from the mean value for 
the controls.) The hepatic mRNA 5α-reductase 
level also correlated negatively (albeit more 
weakly than 5β-reductase) with circulating bile 
acids (r 2 = 0.22, P<0.001) and cortisol (r 2 = 0.13, 
P = 0.005).
Levels of 11β-HSD1 mRNA in liver were re-
duced by 80% in patients, as compared with 
controls (ratio, 0.20 [interquartile range, 0.12 to 
0.37] vs. 1.01 [interquartile range, 0.62 to 1.36], 
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Figure 3. Activity of Cortisol-Metabolizing Enzymes, as Estimated from Ratios of Cortisol Metabolites in 24-Hour Urine Samples.
Enzyme activities were estimated in 36 patients and 15 controls on the basis of urinary metabolites quantified with the use of gas chroma-
tography–mass spectrometry. The overall activity of 11β-hydroxysteroid dehydrogenases (11β-HSDs) was calculated as the ratio of a combina-
tion of 5α-tetrahydrocortisol and 5β-tetrahydrocortisol to tetrahydrocortisone (Panel A), which reflects the relative balance of the cortisone–
cortisol interconversion. The activity of renal 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) was estimated by calculating the ratio 
of cortisone to cortisol (Panel B). The activity of 5α-reductase was estimated by calculating the ratio of 5α-tetrahydrocortisol to cortisol 
(Panel C). The activity of 5β-reductase was estimated by calculating the ratio of 5β-tetrahydrocortisol to cortisol (in Panel D) and the ratio 
of tetrahydrocortisone to cortisone (Panel E). In Panels A through E, the bars represent means, and the T bars standard errors. The lower 
panels show the correlations of the level of total bile acids (in log10 values) with the activity of 5α-reductase as estimated by calculating 
the ratio of 5α-tetrahydrocortisol to cortisol (Panel F), the activity of 5β-reductase activity as estimated by calculating the ratio of 5β- 
tetrahydrocortisol to cortisol (Panel G), and the activity of 5β-reductase as estimated by calculating the ratio of tetrahydrocortisone to 
cortisone (Panel H). The red lines in the three lower panels indicate the regression lines, and the shaded areas represent 95% confi-
dence intervals.
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P<0.001), whereas 11β-HSD1 protein and en-
zyme activity were unaltered. These levels were 
unrelated to the elevated cortisol levels, despite an 
inverse correlation with bile acids (r2 = 0.26 for 
mRNA, P<0.001; r2 = 0.16 for protein, P = 0.005).
Levels of 11β-HSD1 mRNA in adipose tissue 
were reduced by 73% in patients, as compared 
with controls (ratio, 0.27 [interquartile range, 
0.16 to 0.46] vs. 1.00 [interquartile range, 0.60 
to 2.09], P = 0.003) and by 82% in subcutaneous 
adipose tissue (ratio, 0.18 [interquartile range, 
0.07 to 0.30] vs. 1.00 [interquartile range, 0.56 
to 2.17], P<0.001). These levels were unrelated to 
elevated cortisol levels, despite an inverse correla-
tion with bile acids (r2 = 0.28 for subcutaneous 
adipose tissue, P = 0.008). Levels of 11β-HSD1 
protein and in vitro enzyme activity in adipose 
tissue were unaltered.
Discussion
In our study, elevated cortisol levels in critically 
ill patients were only partially explained by an 
increase of 83% in cortisol production, as com-
pared with controls. Since corticotropin levels 
were paradoxically low in the patients, a pitu-
itary-independent mechanism was suggested. We 
showed that impaired cortisol clearance contrib-
uted to hypercortisolemia, as suggested by stud-
ies conducted in the 1950s before the advent of 
ICUs.35,36 Reduced cortisol clearance could be ex-
plained by suppressed levels of A-ring reductases 
and 11β-HSD2.
In other circumstances of reduced cortisol me-
tabolism, such as congenital 11β-HSD2 deficien-
cy,37 negative feedback on the HPA-axis results in 
compensatory down-regulation of cortisol secre-
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Figure 4. Tissue Expression of Cortisol-Metabolizing Enzymes in Relation to Circulating Levels of Cortisol and Bile Acids.
Shown are the results, for 44 patients and 20 controls, of studies evaluating total bile acids (Panel A), 5β-reductase messenger RNA 
(mRNA) (Panel B), and 5β-reductase protein (Panel C). In Panels A, B, and C, the bars represent means, and the T bars standard errors. 
The lower panels show the correlations of the 5β-reductase protein level or total bile acid level (in log10 values) with the plasma level of 
cortisol (Panel D), 5β-reductase mRNA (Panel E), and 5β-reductase protein (Panel F). The red lines in the three lower panels indicate re-
gression lines, and the shaded areas represent 95% confidence intervals. The mRNA data, which have been normalized for glyceraldehyde-
3-phosphate-dehydrogenase (GAPDH) expression, are expressed as the factor difference from the mean value for the controls. The pro-
tein data, which have been normalized for cytokeratin 18 protein expression, are also expressed as the factor difference from the mean 
value for the controls.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EDINBURGH LIB on June 6, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 368;16 nejm.org april 18, 20131486
tion, with lower corticotropin levels and adreno-
cortical atrophy. Elevated levels and production 
of cortisol in patients being treated in the ICU 
must reflect an ongoing stimulus to cortisol se-
cretion. In the presence of low corticotropin lev-
els, increased sensitivity to corticotropin might 
play a role. However, this seems unlikely during 
critical illness, since cortisol responses to corti-
cotropin stimulation are not increased. More likely 
candidates are neuropeptides, catecholamines, or 
cytokines,10 especially since cytokine levels were 
substantially elevated and were positively corre-
lated with cortisol production. The role of cyto-
kines is further corroborated by the finding that 
only patients with pronounced inflammation had 
a level of cortisol production that was higher 
than the level in controls, whereas cortisol clear-
ance was suppressed regardless of the inflamma-
tory status. It remains to be investigated whether 
adrenocortical atrophy is associated with a sus-
tained reduction in the activation of corticotro-
pin receptors on adrenocortical cells in patients 
with reduced cortisol clearance. However, such a 
mechanism would explain the high incidence of 
adrenal vascular instability in surgical patients 
with prolonged critical illness38 and is supported 
by our observation that the patients with the least 
response to corticotropin stimulation had the low-
est cortisol production and the lowest cortisol 
clearance, despite a similar baseline cortisol level, 
as compared with the other patients.
Although in isolation each of the separate 
studies is suggestive, the corroboration of the 
findings with the use of multiple approaches is 
helpful for making conclusions. Urinary excre-
tion of cortisol was elevated in the critically ill 
patients, but cortisol metabolite levels were nor-
mal or low, despite increased cortisol produc-
tion; this pattern is quite different from that in 
Cushing’s syndrome.29,39 The ratios of urinary 
cortisol metabolites suggested reduced activity of 
the A-ring reductases in the critically ill patients 
and a net suppression of cortisol-to-cortisone 
conversion. This interpretation was corroborated 
by low mRNA and protein levels and low activity 
of the A-ring reductases in liver-biopsy samples. 
Unfortunately, kidney samples were unavailable 
to quantify 11β-HSD2 levels. However, the stable-
isotope study showed impaired cortisone gener-
ation in the critically ill patients, indicating sup-
pressed 11β-HSD2 activity. Moreover, 11β-HSD1 
protein and enzyme activity in biopsy samples and 
in vivo D3-cortisol generation were unaltered, so 
it is unlikely that altered regeneration of cortisol 
from cortisone played a role in the patients.
Although hypoperfusion of cortisol-metabo-
lizing organs could theoretically reduce cortisol 
breakdown, this factor does not explain our find-
ings. In contrast, bile acids are known to be com-
petitive inhibitors and transcriptional suppressors 
of cortisol-metabolizing enzymes.13-15 Observa-
tions in patients and animals with cholestasis 
support the inhibition of glucocorticoid metabo-
lism by bile acids.14,15,40 The negative correlation 
between the expression and activity of the A-ring 
reductases and circulating bile acid levels sug-
gests that elevated levels of bile acids may reduce 
cortisol metabolism in critically ill patients, a 
hypothesis that should be further investigated.
Our studies have some limitations. First, it 
would have been ideal to document all the 
changes in a single patient population; this was 
not feasible, in part for ethical reasons. Howev-
er, the five groups of patients were matched, and 
the results of all studies corroborated our hypoth-
esis of reduced cortisol breakdown. Second, biopsy 
samples were obtained on autopsy, which may 
have introduced bias. However, reduced cortisol 
clearance was clearly also present in the patients 
who survived.
These findings have clinical implications. The 
contribution of reduced cortisol breakdown to 
hypercortisolemia during critical illness changes 
our understanding of the stress response. Re-
duced inactivation of cortisol may be important 
not only to increase circulating levels but also to 
potentiate cortisol levels and activity within the 
vital tissues that express inactivating enzymes. 
More pragmatically, the data suggest that “stress 
doses” of hydrocortisone (200 mg per day), which 
are advocated to replace cortisol production in 
critically ill patients who are presumed to have 
adrenal failure, are at least three times too 
high.21 Finally, our data suggest that a low cor-
tisol response to corticotropin stimulation does 
not necessarily reflect adrenal failure, since cor-
tisol production in critically ill patients is not 
subnormal and the suppressed clearance main-
tains hypercortisolemia. Our results may there-
fore help to explain why studies investigating the 
effect of the daily administration of 200 mg of 
hydrocortisone in patients with sepsis (on the 
basis of a low cortisol response to corticotropin 
stimulation) have had conflicting results.5,7
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In conclusion, in critically ill patients in the 
ICU, reduced cortisol breakdown appeared to 
contribute to abnormal blood cortisol levels. This 
finding has potential implications for the diag-
nosis of adrenal failure and its treatment in the 
ICU setting.
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